Methicillin-Resistant Staphylococcus aureus Infections in Patients With Renal Disorders: A Review

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) infection is a rapidly escalating global health burden. It is not only restricted to patients in the hospital settings but has also rooted deeply in the community settings. With increasing prevalence of life style and kidney diseases, the prevalence of MRSA infections is also expected to rise. MRSA infection plays a major role in renal disorders due to its direct vascular access (VA) thereby making patients undergoing dialysis and renal transplant more vulnerable to infections. Prolonged hospital stay, close proximity to MRSA-infected individual, exposure to broad-spectrum antibiotics, surgery and presence of foreign bodies such as central venous catheters predispose an individual to MRSA infection. Current panel of antibiotic treatment includes vancomycin, teicoplanin, linezolid, daptomycin, tigecycline and ceftaroline. However, emergence of resistant strains and several undesirable features pertaining to safety and tolerability of these drugs have led to limited options available for the management of multidrug-resistant MRSA infection in patients with renal disorders. Therefore, there is an increasing need for developing a new potent antibacterial agent with established renal safety that decreases the mortality and morbidity rates in MRSA-infected renal patients.

Management of community-acquired bacterial pneumonia in adults: Limitations of current antibiotics and future therapies

“…Dose modifications in drugs such as vancomycin and daptomycin are necessary for patients with renal failure. [42]…”

16S rRNA Profiling of Nine Global New Strains of Staphylococcus aureus Isolated from Clinical Specimens in Basrah Province, Iraq

“…In recent years, methicillin-resistant Staphylococcus aureus (MRSA) infections have grown at an alarming rate. Infection with MRSA is an increasingly growing global risk to health (Singh et al, 2019).…”

“…The 24 isolates were identified as S. aureus. The 16SrRNA showed the nine strains of Staphylococcus aureus isolates (No.1,2,4,6,8,9,17,25 and 26) had many differences when compared with their reference strains. These isolates were reported as new global separated strains and published by the National Center for Biotechnology Information (NCBI) and European Nucleotide Archive (ENA), as Staphylococcus aureus TSH-…”

Pharmacokinetic and Biomarker Quantification Studies on Vancomycin-Loaded PEGylated Liposomes and Its Potential to Reduce Vancomycin-Induced Kidney Injury: A Rat Study

“…Vancomycin is a commonly used antibiotic in hospital settings, especially against Methicillin-resistant staphylococcus aureus (MRSA) [ 1 ]. Patients infected with MRSA in critical care settings are likely to have co-morbidities such as chronic kidney disease [ 2 ]. Kidney injury is also a major adverse event of vancomycin in adults.…”